



Medi-Cal Rx

Medi-Cal Rx Monthly Bulletin

July 1, 2026

Medi-Cal Rx has implemented or scheduled the following updates. Stay up to date with all that is happening at Medi-Cal Rx by visiting the [Bulletins & News](#) page and signing up for the [Medi-Cal Rx Subscription Service](#) to receive notification of future publications.

1. [Updates to the Medi-Cal Rx Contract Drugs List](#)
2. [Updates to the Medi-Cal Rx Contract Drugs List – Authorized Drug Manufacturer Labeler Codes](#)
3. [Updates to the Medi-Cal Rx Provider Manual](#)
4. [Coming Soon: Basaglar® \(Insulin Glargine\) to Be Removed from the Medi-Cal Rx Contract Drugs List, Effective August 9, 2026](#)
5. [Updates to the Medi-Cal Rx Finance Portal Job Aid](#)
6. [Updates to the Medi-Cal Rx Enteral Nutrition Prior Authorization Request \(DHCS 6505\) Form](#)
7. [Updates to the Prior Authorization Request \(DHCS 6560\) Form](#)

1. Updates to the Medi-Cal Rx Contract Drugs List

The following updates have been made to the [Medi-Cal Rx Contract Drugs List](#) (CDL) and the [Medi-Cal Rx Diagnosis Crosswalk](#) *.

Drug Name	Description
Azilsartan Medoxomil/ Chlorthalidone	Labeler restriction (LR) added.
Cannabidiol	LR added.
Ciprofloxacin HCL/Hydrocortisone	LR 00078 removed.
Doravirine/Islatravir	Added to the CDL with LR.
Dornase Alfa	LR added.
Epoetin Alfa-epbx	Added to the CDL with LR.
Estradiol	LR added to the vaginal rings.
Glatiramer Acetate	Effective August 1, 2026: LR removed.
Mometasone Furoate	LR added to aerosol inhaler and oral powder for inhalation.
Mometasone/Formoterol	LR added.
Polyethylene Glycol 3350/Sodium Sulfate/Potassium Chloride/ Magnesium Sulfate/Sodium Chloride	Additional LR (24338) added.
Remibrutinib *	Added to the CDL with QL, LR, and diagnosis restrictions.
Risperidone	LR added to extended-release single-dose prefilled syringes.
Semaglutide (Ozempic)	Additional strengths (1.5 mg, 4 mg, 9 mg tablets) added to the CDL with LR and diagnosis restrictions.
Sodium Sulfate/Potassium Chloride/Magnesium Sulfate	Additional LR (24338) added.
Ticagrelor	Effective August 1, 2026: LR removed.
Ulipristal Acetate	LR removed.

2. Updates to the Medi-Cal Rx Contract Drugs List – Authorized Drug Manufacturer Labeler Codes

The following updates have been made to the [Medi-Cal Rx Contract Drugs List – Authorized Drug Manufacturer Labeler Codes](#).

Labeler Code Additions

Drug Name	Description
11788	AIPING PHARMACEUTICALS, INC.
73308	AYURAX
50633	BTG INTERNATIONAL INC
84976	DENALI THERAPEUTICS INC.
85320	EDDINGPHARM (U. S.) INC.
72874	GE HEALTHCARE INC.
72303	HEC PHARM USA INC.
85742	KANCHAN HEALTHCARE INC
87137	MATTHIAS THERAPEUTICS, LLC
17156	MEDI-PHYSICS INC. DBA GE HEALTHCARE
64281	METHAPHARM INC.
67850	METHAPHARM, INC
62993	MOREPEN LABORATORIES LIMITED
70244	SENTISS PHARMACEUTICALS, LLC
69499	SOLUBIOMIX, LLC
85972	STELLON BIOTECH INC.
45567	SUN PHARMACEUTICAL INDUSTRIES, INC.
60290	UMEDICA LABORATORIES USA INC.
87262	USWM CT, LLC
85006	VALORUM BIOLOGICS, LLC

Labeler Code Terminations

Drug Name	Description
69853	ALEXION PHARMACEUTICALS, INC.
69660	CLOVIS ONCOLOGY, INC.
73079	EIGER BIOPHARMACEUTICALS INC.
85633	ESTIVA GENERICS
71800	INNOVIDA PHARMACEUTIQUE CORPORATION
45861	PHARMACEUTICA NORTH AMERICA, INC.
72928	Q BIOMED, INC.
13925	SETON PHARMACEUTICALS, LLC
54879	STI PHARMA, LLC
00941	VANTIVE US HEALTHCARE LLC
00206	WYETH PHARMACEUTICALS LLC
42195	XPIRE PHARMA LLC
69117	YILING PHARMACEUTICAL, INC
82036	ZAMBON USA, LTD

3. Updates to the Medi-Cal Rx Provider Manual

The following updates/additions have been made to the [Medi-Cal Rx Provider Manual](#).

Section	Update Description
<i>Section 15.1.1 – Dispensing Quantity Limitations</i>	Removed language about over-the-counter (OTC) antihistamines.
<i>Appendix G – OHC Carrier Information</i>	Updated contact information about Other Health Coverage (OHC) carriers.

4. Coming Soon: Basaglar® (Insulin Glargine) to Be Removed from the Medi-Cal Rx Contract Drugs List, Effective August 9, 2026

What Prescribers Need to Know

Effective August 9, 2026, Basaglar® (insulin glargine), NDC labeler code 00002, will be removed from the [CDL](#). Claims submitted for this drug without an approved prior authorization (PA), with a date of service (DOS) on or after August 9, 2026, will deny with **Reject Code 606 – Brand Drug/Specific Labeler Code Required**. A PA request demonstrating medical justification for use over a CDL-listed product will need to be submitted for coverage consideration.

What Prescribers Need to Do

- Prescribers should consider alternate covered therapies that are listed on the CDL (such as Lantus® [insulin glargine] or insulin glargine-yfgh), if clinically appropriate. Refer to the [Medi-Cal Rx Approved NDC List](#) on the [Medi-Cal Rx Web Portal](#).
- If a change in therapy is not appropriate, beginning August 9, 2026, submit a PA request via one of the five approved PA request submission methods demonstrating medical justification:
 - [CoverMyMeds®](#)
 - [Medi-Cal Rx Secured Provider Portal](#)
 - NCPDP P4 Transaction
 - Fax
 - U.S. Mail

5. Updates to the Medi-Cal Rx Finance Portal Job Aid

Medi-Cal Rx published updates to the [Medi-Cal Rx Finance Portal Job Aid](#) on June 11, 2026. To access the document, visit the [Medi-Cal Rx Provider Portal](#) and select the **Reference Materials** tab on the [Forms & Information](#) page.

6. Updates to the Medi-Cal Rx Enteral Nutrition Prior Authorization Request (DHCS 6505) Form

Medi-Cal Rx published updates to the [Medi-Cal Rx Enteral Nutrition Prior Authorization Request \(DHCS 6505\)](#) form on June 12, 2026. To access the document, visit the [Medi-Cal Rx Provider Portal](#) and select the **Reference Materials** tab on the [Forms & Information](#) page.

7. Updates to the Prior Authorization Request (DHCS 6560) Form

Medi-Cal Rx published updates to the [Medi-Cal Rx Prior Authorization Request \(DHCS 6560\)](#) form on June 12, 2026. To access the document, visit the [Medi-Cal Rx Provider Portal](#) and select the **Reference Materials** tab on the [Forms & Information](#) page.

Contact Information

You can call the Medi-Cal Rx Customer Service Center (CSC) at 1-800-977-2273, which is available 24 hours a day, 7 days a week, 365 days per year.

For other questions, email Medi-Cal Rx Education & Outreach at MediCalRxEducationOutreach@primetherapeutics.com.